Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Increased risk of osteoporosis following commonly used first-line treatments for lymphoma : a Danish Nationwide Cohort Study. / Baech, Joachim; Hansen, Steen Moeller; Jakobsen, Lasse Hjort; Øvlisen, Andreas K; Severinsen, Marianne Tang; Brown, Peter de Nully; Vestergaard, Peter; Frederiksen, Henrik; Jørgensen, Judit; Starklint, Jørn; Josefsson, Pär; Hammer, Troels; Clausen, Michael Roost; Torp-Pedersen, Christian; Jensen, Paw; El-Galaly, Tarec Christoffer.

I: Leukemia and Lymphoma, Bind 61, Nr. 6, 06.2020, s. 1345-1354.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Baech, J, Hansen, SM, Jakobsen, LH, Øvlisen, AK, Severinsen, MT, Brown, PDN, Vestergaard, P, Frederiksen, H, Jørgensen, J, Starklint, J, Josefsson, P, Hammer, T, Clausen, MR, Torp-Pedersen, C, Jensen, P & El-Galaly, TC 2020, 'Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study', Leukemia and Lymphoma, bind 61, nr. 6, s. 1345-1354. https://doi.org/10.1080/10428194.2020.1723015

APA

Baech, J., Hansen, S. M., Jakobsen, L. H., Øvlisen, A. K., Severinsen, M. T., Brown, P. D. N., Vestergaard, P., Frederiksen, H., Jørgensen, J., Starklint, J., Josefsson, P., Hammer, T., Clausen, M. R., Torp-Pedersen, C., Jensen, P., & El-Galaly, T. C. (2020). Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study. Leukemia and Lymphoma, 61(6), 1345-1354. https://doi.org/10.1080/10428194.2020.1723015

CBE

Baech J, Hansen SM, Jakobsen LH, Øvlisen AK, Severinsen MT, Brown PDN, Vestergaard P, Frederiksen H, Jørgensen J, Starklint J, Josefsson P, Hammer T, Clausen MR, Torp-Pedersen C, Jensen P, El-Galaly TC. 2020. Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study. Leukemia and Lymphoma. 61(6):1345-1354. https://doi.org/10.1080/10428194.2020.1723015

MLA

Vancouver

Baech J, Hansen SM, Jakobsen LH, Øvlisen AK, Severinsen MT, Brown PDN o.a. Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study. Leukemia and Lymphoma. 2020 jun;61(6):1345-1354. https://doi.org/10.1080/10428194.2020.1723015

Author

Baech, Joachim ; Hansen, Steen Moeller ; Jakobsen, Lasse Hjort ; Øvlisen, Andreas K ; Severinsen, Marianne Tang ; Brown, Peter de Nully ; Vestergaard, Peter ; Frederiksen, Henrik ; Jørgensen, Judit ; Starklint, Jørn ; Josefsson, Pär ; Hammer, Troels ; Clausen, Michael Roost ; Torp-Pedersen, Christian ; Jensen, Paw ; El-Galaly, Tarec Christoffer. / Increased risk of osteoporosis following commonly used first-line treatments for lymphoma : a Danish Nationwide Cohort Study. I: Leukemia and Lymphoma. 2020 ; Bind 61, Nr. 6. s. 1345-1354.

Bibtex

@article{28c68071efe04b7c8aebcc42404cbb0d,
title = "Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study",
abstract = "High-dose prednisolone is used in first-line treatment for lymphoma, but the potential adverse impact on bone health is unclear. Danish patients with diffuse large B-cell lymphoma or follicular lymphoma diagnosed between 2000 and 2012 were matched to the background population. Osteoporotic events (osteoporosis treatment or low-energy fracture) were identified using the Danish National Patient Registry and Prescription Registry. In total, 2589 patients and 12,945 controls were included. Lymphoma patients had increased risk of osteoporotic events compared to the matched population (hazard ratio 1.61 [95% confidence interval 1.40;1.84]). The 5- and 10-year cumulative risks of osteoporotic events for lymphoma patients were 10.0% [8.6;11.4] and 16.3% [13.8;18.7], whereas corresponding risks in the background population were 6.8% [6.3;7.3] and 13.5% [12.4;14.6]. Patients without osteoporotic event in the first two years after treatment were not at higher risk of osteoporotic events in subsequent years. Risk factors for osteoporotic events were female sex and age >70 years.",
author = "Joachim Baech and Hansen, {Steen Moeller} and Jakobsen, {Lasse Hjort} and {\O}vlisen, {Andreas K} and Severinsen, {Marianne Tang} and Brown, {Peter de Nully} and Peter Vestergaard and Henrik Frederiksen and Judit J{\o}rgensen and J{\o}rn Starklint and P{\"a}r Josefsson and Troels Hammer and Clausen, {Michael Roost} and Christian Torp-Pedersen and Paw Jensen and El-Galaly, {Tarec Christoffer}",
year = "2020",
month = jun,
doi = "10.1080/10428194.2020.1723015",
language = "English",
volume = "61",
pages = "1345--1354",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor & Francis ",
number = "6",

}

RIS

TY - JOUR

T1 - Increased risk of osteoporosis following commonly used first-line treatments for lymphoma

T2 - a Danish Nationwide Cohort Study

AU - Baech, Joachim

AU - Hansen, Steen Moeller

AU - Jakobsen, Lasse Hjort

AU - Øvlisen, Andreas K

AU - Severinsen, Marianne Tang

AU - Brown, Peter de Nully

AU - Vestergaard, Peter

AU - Frederiksen, Henrik

AU - Jørgensen, Judit

AU - Starklint, Jørn

AU - Josefsson, Pär

AU - Hammer, Troels

AU - Clausen, Michael Roost

AU - Torp-Pedersen, Christian

AU - Jensen, Paw

AU - El-Galaly, Tarec Christoffer

PY - 2020/6

Y1 - 2020/6

N2 - High-dose prednisolone is used in first-line treatment for lymphoma, but the potential adverse impact on bone health is unclear. Danish patients with diffuse large B-cell lymphoma or follicular lymphoma diagnosed between 2000 and 2012 were matched to the background population. Osteoporotic events (osteoporosis treatment or low-energy fracture) were identified using the Danish National Patient Registry and Prescription Registry. In total, 2589 patients and 12,945 controls were included. Lymphoma patients had increased risk of osteoporotic events compared to the matched population (hazard ratio 1.61 [95% confidence interval 1.40;1.84]). The 5- and 10-year cumulative risks of osteoporotic events for lymphoma patients were 10.0% [8.6;11.4] and 16.3% [13.8;18.7], whereas corresponding risks in the background population were 6.8% [6.3;7.3] and 13.5% [12.4;14.6]. Patients without osteoporotic event in the first two years after treatment were not at higher risk of osteoporotic events in subsequent years. Risk factors for osteoporotic events were female sex and age >70 years.

AB - High-dose prednisolone is used in first-line treatment for lymphoma, but the potential adverse impact on bone health is unclear. Danish patients with diffuse large B-cell lymphoma or follicular lymphoma diagnosed between 2000 and 2012 were matched to the background population. Osteoporotic events (osteoporosis treatment or low-energy fracture) were identified using the Danish National Patient Registry and Prescription Registry. In total, 2589 patients and 12,945 controls were included. Lymphoma patients had increased risk of osteoporotic events compared to the matched population (hazard ratio 1.61 [95% confidence interval 1.40;1.84]). The 5- and 10-year cumulative risks of osteoporotic events for lymphoma patients were 10.0% [8.6;11.4] and 16.3% [13.8;18.7], whereas corresponding risks in the background population were 6.8% [6.3;7.3] and 13.5% [12.4;14.6]. Patients without osteoporotic event in the first two years after treatment were not at higher risk of osteoporotic events in subsequent years. Risk factors for osteoporotic events were female sex and age >70 years.

U2 - 10.1080/10428194.2020.1723015

DO - 10.1080/10428194.2020.1723015

M3 - Journal article

C2 - 32043382

VL - 61

SP - 1345

EP - 1354

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 6

ER -